RBDCOV | COVID-19 vaccine trials with immunocompromising conditions launched in Turkey

All the volunteers are adults affected by different pathologies or immunosuppressive conditions whose immune system may be less responsive to vaccines.

All the volunteers are adults affected by different pathologies or immunosuppressive conditions whose immune system may be less responsive to vaccines.
January 23, 2023

One of the objectives of the RBDCOV project is to test whether the vaccine can reactivate or re-generate a protective immune response to SARS-CoV-2 in immunocompetent and immunosuppressed individuals

Accordingly, within the RBDCOV project a clinical trial in Turkey for HIPRA’s COVID-19 vaccine in people with immunocompromising conditions has recently started, aiming at determining whether an additional dose of HIPRA’s COVID-19 vaccine can generate an immune response in people living with immune system disorders or who are receiving immunosuppressive treatments.

This study will determine if the vaccine is able to reactivate or re-generate a sufficient immune response and increase the activity of the immune system (natural defences) to SARS-CoV-2. Additionally, the safety of this new vaccine will be assessed, and it will be studied if it can prolong the effect of earlier vaccination that the participants have already received.

Asphalion is proud regulatory partner of RBDCOV by carrying out the regulatory pathway throughout the whole project by seeking scientific advice for the RBDCOV clinical trials with the European regulatory authorities, preparing the required documents to support clinical trial applications and supporting the preparation of the eCTD registration dossier currently under rolling review, among other regulatory activities.

For more details about the project, have a look at the project´s website: RBDCOV Project Website

For further information, you can contact us at: [email protected]

 

Search News & Events

  • Filter by category

Share

Related news and events

HORIZON EUROPE | NABIHEAL progress meeting

Two years into the NABIHEAL project, Asphalion experts Marta Rayo Lunar and Sergio Veiga attended the consortium meeting in Zagreb, hosted by IMI, to review

HORIZON EUROPE PROJECT | KeratOPrinter Kick-Off Meeting

Corneal blindness affects over 11.7 million people worldwide, yet only 1 in 70 patients receive a corneal transplant due to a severe donor shortage. The KeratOPrinter project aims to address this gap by developing a groundbreaking 4D bioprinting suite capable of producing fully functional, biocompatible human corneas. Combining expertise from world-class partners, the project focuses on scalable cell sources, advanced bioinks, high-precision bioprinting, clinical handling solutions, regulatory compliance, and a strong collaborative network. By 2035, KeratOPrinter seeks to revolutionize corneal transplantation and restore vision for millions.

ARDAT PROJECT

A new year, new classes, and a deep dive into advanced therapies, including discussions on the ARDAT project, as part of the University of Sheffield’s

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting